VERAXA Biotech Expands Human-Relevant Testing to Advance BiTAC Cancer Therapies
VERAXA Biotech (VRXA) is expanding human-relevant preclinical testing for its cancer therapies, using 3D tumor models and patient-derived samples. Its lead BiTAC T-cell engager showed potent tumor-cell killing in 10 lung cancer models, requiring fewer mice. The approach aims to accelerate drug development and reduce animal testing. According to the company, this could lower failure rates and costs, aligning with regulatory trends.

